Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$6.56 USD
+0.13 (2.02%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $6.58 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Mesoblast Limited (MESO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.00 | $11.00 | $11.00 | 71.07% |
Price Target
Only one analyst offered a short-term price target of $11.00 for Mesoblast Limited. This represents an increase of 71.07% from the last closing price of $6.43.
Analyst Price Targets (1 )
Broker Rating
Mesoblast Limited currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MESO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/23/2024 | Piper Sandler | Edward A Tenthoff | Hold | Strong Buy |
7/16/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/20/2024 | Maxim Group | Michael Okunewitch | Hold | Hold |
6/4/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 4 |
Average Target Price | $11.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | NA |